Previous Statements by CELG
» Celgene Q1 2010 Earnings Call Transcript
» Celgene Corporation Q4 2009 Earnings Call Transcript
» Celgene Corporation Q3 2009 Earnings Call Transcript
Also, our discussions during this conference call will include certain non-GAAP financial measures. Non-GAAP financial measures provide investors and management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available as part of our earnings releases on Celgene's website at www.celgene.com in the Investor Relations section.I will now turn the call over to our Chief Executive Officer, Bob Hugin. Robert Hugin Thank you, Tim. The second quarter was an outstanding quarter for Celgene across all functions and geographies. Our exceptional global team produced full of excellent operating results and achieved multiple significant milestones that has a potential to create meaningful benefits for patients and strong returns for shareholders for years to come. Early this morning, we announced record-financial results with total revenue growing 36% year-over-year to $850 million and non-GAAP earnings per share increasing 50% year-over-year to $0.69. Before we review the specific operating and financial results of the quarter, I'd like to highlight several of the key strategic developments of the last three months. Though not yet completed, the announcement of Abraxis BioScience acquisition broadens our therapeutic focus into the solid tumor market. Their lead product, ABRAXANE, which is approved for the treatment of metastatic breast cancer in the United States and international markets, has also shown significant promise in pancreatic and non-small cell lung cancer clinical trials. The transaction provides the opportunity for us to leverage our global, commercial, clinical and regulatory organizations and further strengthens our pipeline, which multiple candidates from the Abraxis' proprietary Nab Technology portfolio. Advancing our hematology pipeline is also a strategic imperative. At the American Society of Clinical Oncology and European Hematology meetings in June, there were many presentations that highlighted important new data supporting our key products and programs. Perhaps the most significant data were results from three Phase III studies, demonstrating the substantial benefit achieved by multiple myeloma patients receiving continuous REVLIMID therapy.
Our international expansion strategy continues to be an important growth driver for our products. On June 25, REVLIMID was approved in Japan for the treatment of second-line multiple myeloma. Governmental reimbursement was achieved in less than a month following approval, actually reflecting the importance of REVLIMID therapy in myeloma and a validation of the quality of the planning and execution of the Celgene team in Japan.We are now in the early stages of a thoughtfully-planned commercial launch in this, the second largest oncology market in the world. The investments we have made in Japan and in other international markets will enable us to capture the full value of REVLIMID and the many other opportunities in our pipeline in all major markets. During the quarter, substantial progress was achieved in advancing multiple pipeline programs, highlighted by the initiation of our first pivotal Phase III trial for our lead anti-inflammatory product, apremilast, in psoriatic arthritis, and the initiation of our Phase I cancer clinical study of our novel dual mTOR Kinase Inhibitor CC-223, a product of our research labs in San Diego. The significant progress in this quarter further strengthens our belief that sustained long-term growth comes best through an unwavering commitment to invest in multiple programs designed to produce breakthrough therapies for patients with serious unmet medical needs. I'd like now to hand the call over to Dave Gryska, our Chief Financial Officer, who will review our second quarter financial results. Dave? Read the rest of this transcript for free on seekingalpha.com